CNS and GI Motility Medications GLP-1 interactions with CNS and GI medications often require a personalized approach
This phenomenon, documented in multiple metabolic studies, means the "fat content" on the label doesn't translate directly to absorbed fat
These symptoms typically emerge during dose escalation and often diminish over 4-8 weeks as tolerance develops
OBESITY AND IBD by @EdwardLoftus2 Obesity is a chronic inflammatory statue Adipose tissue is not biologically inert (TNFa, IL-6, IL-8, leptin, adiponectin) Postulated role in the pathogenesis of IBD Potential risk factor for adverse outcomes Trends in BMI among IBD patients at diagnosis in Olmsted County, Doubling of obesity rates in 20 years in CD and UC (Johnson AM JCC 2021 and J Clin Gastro 2024) Obese patients more likely to have a colonic phenotype
Beware of claims like Lose 50 pounds in 6 weeks! or No diet or exercise needed! GLP-1s are effective but work gradually over months, and theyre most successful when combined with lifestyle changes
Ingredients like berberine and chromium, as we established, support metabolism and blood sugar, which adds to their effectiveness